Special Populations and Immune Checkpoint Inhibitors: Are They Safe?

episode

Keeping Current CME not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Inherited Mindset: Firing Your Family’s Financial Beliefs 3 min · 27 Sep 2026 · The Level Up Podcast w/ Paul Alex

The Rise of the AI Moderates 32 min · 27 Sep 2026 · The AI Daily Brief: Artificial Intelligence News and Analysis

7AM ET 09/27/2026 Newscast 3 min · 27 Sep 2026 · Fox News Hourly Update

The Sunday Paper Review 27th September 31 min · 27 Sep 2026 · The Pat Kenny Show

Danielle with… Amber Glenn and Pasha Pashkov 1h 0m · 27 Sep 2026 · Pod Meets World

Khvicha Kvaratskhelia - The Football Interview 9 min · 27 Sep 2026 · Football Daily

Report any issue

Source

Recorded26 Feb 2021

Publisherkeepingcurrentcme.libsyn.com ↗

Handlerec:4300042

Show notes

In this activity, three experts discuss how to incorporate immune checkpoint inhibitor therapy into the management of individuals classified as part of the "special population" of patients not generally included in clinical trials. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/946383?src=mkm_podcast_addon_946383

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in